Strength and durability of antibody responses to BNT162b2 and CoronaVac
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2022.02.11.22270848: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Ethics: Written informed consent was obtained from all participants.
IRB: The study protocols were approved by the Institutional Review Board of the University of Hong Kong.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:There are a number of limitations of our study. First, we did not measure neutralizing …
SciScore for 10.1101/2022.02.11.22270848: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Ethics: Written informed consent was obtained from all participants.
IRB: The study protocols were approved by the Institutional Review Board of the University of Hong Kong.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:There are a number of limitations of our study. First, we did not measure neutralizing antibody against live SARS-CoV-2 but used a surrogate neutralization assay which has a high correlation with live virus neutralization titers [16]. We did not assess antibodies against variants such as Delta or Omicron, but expect antibody levels to be reduced against variants as reported in other studies [16, 17]. We did not assess T cell responses which could contribute to protection against severe disease and could be less affected by variants [18]. In conclusion, we identified weaker boosting and faster waning of antibodies against SARS- CoV-2 in recipients of CoronaVac compared to BNT162b2, and would expect this to correlate with lower levels of protection against symptomatic infection for CoronaVac. In individuals of any age or sex, BNT162b2 responses were stronger and more durable than responses to CoronaVac. The weaker and less durable responses following CoronaVac support earlier provision of third doses to persons who previously received two doses of this vaccine.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a protocol registration statement.
Results from scite Reference Check: We found no unreliable references.
-
